Serving hundreds of leading biopharmaceutical companies globally:

Generated: January 18, 2019

DrugPatentWatch Database Preview

Pembrolizumab - Biologic Drug Details

« Back to Dashboard

Summary for pembrolizumab

Tradenames:	1
Patents:	33
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for pembrolizumab

Pharmacology for pembrolizumab

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions

US Patents for pembrolizumab

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up	Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)	➤ Sign Up	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up		➤ Sign Up	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up	KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)	➤ Sign Up	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up	MedImmune Limited (Cambridge, GB)	➤ Sign Up	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up	Advenchen Pharmaceuticals, LLC (Moorpark, CA)	➤ Sign Up	RX	Orphan	search
Merck Sharp Dohme	KEYTRUDA	pembrolizumab	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER	125514	001	2014-09-04	➤ Sign Up	Flexus Biosciences, Inc. (Princeton, NJ)	➤ Sign Up	RX	Orphan	search
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Patent Expiration	Status	Orphan	Source

International Patents for pembrolizumab

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
European Patent Office	1431311	➤ Sign Up
Australia	2004207494	➤ Sign Up
China	1764478	➤ Sign Up
World Intellectual Property Organization (WIPO)	2016073763	➤ Sign Up
Japan	2009519931	➤ Sign Up
World Intellectual Property Organization (WIPO)	2017210058	➤ Sign Up
Country	Document Number	Estimated Expiration

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla

Fish and Richardson

McKinsey

Federal Trade Commission

Baxter

Covington

UBS

US Department of Justice

Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.